Huntington National Bank’s Madrigal Pharmaceuticals MDGL Stock Holding History

Huntington National Bank’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.6K	Sell	29 -1	-3%	-$512	﹤0.01%	1870
2026 Q1	$15.7K	Buy	30 +1	+3%	+$478	﹤0.01%	1728
2025 Q4	$16.9K	Sell	29 -1	-3%	-$511	﹤0.01%	1634
2025 Q3	$13.8K	Buy	30 +4	+15%	+$1.49K	﹤0.01%	1724
2025 Q2	$7.87K	Hold	26	–	–	﹤0.01%	1859
2025 Q1	$8.61K	Hold	26	–	–	﹤0.01%	1805
2024 Q4	$8.02K	Hold	26	–	–	﹤0.01%	1853
2024 Q3	$5.52K	Buy	26 +1	+4%	+$256	﹤0.01%	1971
2024 Q2	$7K	Sell	25 -25	-50%	-$5.95K	﹤0.01%	1814
2024 Q1	$13.4K	Sell	50 -3	-6%	-$707	﹤0.01%	1599
2023 Q4	$12.3K	Hold	53	–	–	﹤0.01%	1587
2023 Q3	$7.74K	Buy	+53	New	+$9.98K	﹤0.01%	1659

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Huntington National Bank's MDGL Position: Q2 2026 in Review

Huntington National Bank reduced its Madrigal Pharmaceuticals (MDGL) stake by 3.3% in Q2 2026, selling an estimated $512 and leaving 29 shares worth $15.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1870.

Huntington National Bank first reported a position in MDGL in Q3 2023 and has held it in 12 quarters since. The position peaked at $16.9K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Huntington National Bank held 29 shares of Madrigal Pharmaceuticals worth $15.6K as of Q2 2026.
Huntington National Bank sold 1 Madrigal Pharmaceuticals share in Q2 2026, an estimated $512.
Madrigal Pharmaceuticals made up ﹤0.01% of Huntington National Bank's portfolio in Q2 2026, its #1870 holding.
Huntington National Bank first reported a position in Madrigal Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Huntington National Bank's Madrigal Pharmaceuticals position peaked at $16.9K in Q4 2025.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Huntington National Bank's 13F filing for Q2 2026, filed 13 Aug 2026.